---
title: French Single Centre Experience of Critically Ill Patients With Covid 19
nct_id: NCT04354558
overall_status: UNKNOWN
sponsor: Centre Hospitalier Universitaire, Amiens
study_type: OBSERVATIONAL
primary_condition: Epidemiology
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04354558.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04354558"
ct_last_update_post_date: 2023-03-22
last_seen_at: "2026-05-12T07:32:01.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# French Single Centre Experience of Critically Ill Patients With Covid 19

**Official Title:** Epidemiology and Outcomes of Critically Ill Patients With Covid 19: a French Single Centre Experience

**NCT ID:** [NCT04354558](https://clinicaltrials.gov/study/NCT04354558)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Centre Hospitalier Universitaire, Amiens
- **Conditions:** Epidemiology, Sars-CoV2, COVID 19, Critical Care, Prognostic, Survival
- **Start Date:** 2020-07-01
- **Completion Date:** 2023-08
- **CT.gov Last Update:** 2023-03-22

## Brief Summary

Since the outbreak of a syndrome of acute respiratory distress associated to a novel coronavirus 2 (SARS-Cov2) that began in China, Europe and France have to face a sanitary emergency with critically care support when the patient evolves to an acute respiratory distress (ARDS). In the context of supply shortages (ventilators, bed capacities) that countries have to deal with, data were lacking of characteristics and outcomes of patients admitted to intensive care unit (ICU). the purpose of this project is to report the epidemiology and the outcomes of a French cohort of critically ill patients with SARS-Cov2

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years old
* patient with positive rRT PCR of SARS Cov2 on a sample of nasopharyngeal swab
* admission in intensive care unit

Exclusion Criteria:

* patient under 18 years old
```

## Arms

- **survival patients** — The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
- **non-survival patients** — The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay

## Primary Outcomes

- **Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU** _(time frame: from day 1 of admission)_ — Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU
- **Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU** _(time frame: from day 1 of admission)_ — Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU
- **Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU** _(time frame: from day 1 of admission)_ — Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU
- **Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU** _(time frame: from day 1 of admission)_ — Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU
- **Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU** _(time frame: from day 1 of admission)_ — Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU

## Locations (1)

- CHU Amiens, Amiens, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu amiens|amiens||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04354558.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04354558*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*